Psychiatric and behavioral problems: Pharmacological approaches

Taylor and Francis Ltd 6

Volumn 9781410607225, Issue , 2003, Pages 129-141

  Robert, Philippe H ^a  

^a UNIVERSITY HOSPITAL OF NICE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 28744435173     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (44)

1. Allain, H., Dautzenberg, P. H. J., Maurer, K., Schuck, S., Bonhomme, D., & Gerard, D. (2000). Double blind study of tiapride versus haloperidol and placebo in agitation and aggressiveness in elderly patients with cognitive impairment. Psycho-pharmacology, 148(4), 361-366.
2. American Psychiatric Association. (1994). Diagnostic and Statistical Manual of Mental Disorders (4th ed.). Washington, DC: Author.
3. American Psychiatric Association. (1997). Practice guideline for the treatment of patients with Alzheimer's disease and other dementia of late life. American Journal of Psychiatry, 154(Suppl. 5), 1-39.
4. Benoit, M., Dygai, I., Migneco, O., Robert, P. H., Bertogliati, C., Darcourt, J., Benoliel, J., Aubin-Brunet, V., & Pringuey, D. (1999). Behavioral and psychological symptoms in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders, 10, 511-517.
5. Bertogliati, C., Robert, P. H., Lafont, V. Bedoucha, P., Benoît, M., & Salame, P. (2002). Metacognition et maladie d' Alzheimer. Année Gerontologique, 27-31.
6. Borson S., & Raskind, M. A. (1997). Clinical features and pharmacologic treatment of behavioral symptoms of Alzheimer's disease. Neurology, 48(Suppl. 6), 17-24.
7. Burke, W. J., Folks, D. G., Roccaforte, W. H., & Wengel, S. P. (1995). Serotonin reuptake inhibitors for the treatment of coexisting depression and psychosis in dementia of Alzheimer type. American Journal Geriatry Psychiatry, 2, 352-354.
8. Carrier, L., & Brodaty, H. (1996). Mood and behaviour management. In S. Gauthier (Ed.) Clinical diagnosis and management of Alzheimer's disease (pp. 205-218 ). London: Martin Dowitz.
9. Chen, C. P. L. H., Hope, R. A., Adler, J. T., Keene, J., McDonald, B., Francis, P. T., Esiri, M. M., & Bowen, D. M. (1994). Loss of 5HT2A receptors in Alzheimer's disease neocortex is associated with disease severity while preservation of 5HT2Areceptors is associated with anxiety [Abstract]. Annals of Neurology, 36, 308-309.
10. Cohen-Mansfield, J. (1989). Agitation in the ederly. In N. Bilig & P. Rabins (Eds.) Advances in psychosomatic medicine: Geriatric psychiatry (pp. 101-113). Basel: S. Karger AG.
11. Cummings, J. L. (1997). The Neuropsychiatric Inventory: Assessing psychopathology in dementia patients. Neurology, 48 (Suppl. 6), 10-16.
12. Cummings, J. L. (2000). Cholinesterase inhibitors: Anew class of psychotropic compounds. American Journal of Psychiatry, 157(1), 4-15.
13. Cummings, J. L., Diaz, C., & Levy, M. (1996). Behavioral syndromes in neuro degenerative diseases: Frequency and significance.Seminar in Neuropsychiatry, 1, 241-247.
14. Cummings, J. L., Mega, M. S., Gray, K., Rosemberg-Thompson, S., & Gornbein, T. (1994). The Neuropsychiatric Inventory: Comprehensive assessment of psycho-pathology in dementia. Neurology, 44, 2308-2314.
15. Edell, W. S., & Tunis, S. L. (2001). Antipsychotic treatment of behavioral and psychological symptoms of dementia in geropsychiatric inpatients. American Journal of Geriatric Psychiatry, 9, 289-297.
16. Finkel, S. I., Costa Silva, J., Cohen, G., Miller, S., & Sartorius, N. (1996). Behavioral and psychological signs and symptoms of dementia: A consensus statement on current knowledge and implications for research and treatment. International Psychogeriatrics, 8, 497-500.
17. International Psychogeriatric Association. (1998). Behavioral and psychological symptoms of dementia. Educational pack. Macclesfield, UK: Gardiner-Caldwell.
18. Jeste, D. V., Caliguiri, M. P., Paulsen, J. S., Heaton, R. K., Lacro, J. P., Harris, M., & Bailey, A. (1995). Risk of tardive dyskinesia in older patients: A prospective longitudinal study of 266 outpatients. Archives of General Psychiatry, 52, 756-765.
19. Katz, I. R., Jeste, D. V., & Mintzer J. E. (1999). Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: Arandomized, double-blind trial. Journal of Clinical Psychiatry, 60(2), 107-115.
20. Lawlor, B. A., Radcliffe, J., & Molchan, S. E. (1994). A pilot placebo-controlled study of tradozone and buspirone in Alzheimer's disease. International Journal of Geriatric Psychiatry, 9, 55-59.
21. Lawrence, A. D., & Sahakian, B. J. (1995). Alzheimer disease, attention, and the cholinergic system. Alzheimer Disease and Associated Disorders, 9(Suppl. 2), 43-49.
22. Lebert, F., Pasquier, F., & Petit, H. (1994). Behavioral effects of trazodone in Alzheimer's disease. Journal of Clinical Psychiatry, 55, 536-538.
23. Levy, M. L., Cummings, J. L., & Kahn-Rose, R. (1999). Neuropsychiatric symptoms and cholinergic therapy for Alzheimer's disease. Gerontology, 45(Suppl. 1), 15-22.
24. McKeith, L. G., Galasko, D., & Kosaka, K. (1996). Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop. Neurology, 47, 1113-1124.
25. McShane, R., Keene, J., Gedling, K., Fairburn, C., Jacoby, R., & Hope, T. (1997). Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow up. British Medical Journal, 70, 266-314.
26. Migneco, O., Benoit, M., Koulibaly, P. M., Dygai, I., Bertogliati, C., Desvignes, P., Robert, P. H., Malandain, C., Bussiere, F., & Darcourt, J. (2001). Perfusion brain SPECT and statistical parametric mapping analysis indicate that apathy is a cingulate syndrome: Astudy in Alzheimer's disease and nondemented patients. Neuroimage, 13, 896-902.
27. Mortimer, J. A., & Ebbitt, B. (1992). Predictors of cognitive and functional progression in patients with probable Alzheimer's disease. Neurology, 42, 1689-1696.
28. Nyth, A. L., & Gottfries, C. G. (1990). The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. British Journal of Psychiatry, 157, 894-901.
29. Reisberg, B., Borenstein, J., Salob, S. P., Ferris, S. H., & Franssen, E. (1987). Behavioral symptoms in Alzheimer's disease: Phenomenology and treatment. Journal of Clinical Psychiatry, 48(Suppl. 9), 9-15.
30. Robert, P. H., & Allain, H. (2001). Clinical management of agitation in the elderly with tiapride. European Psychiatry, 16(Suppl. 1), 42-47.
31. Robert, P. H., Aubin-Brunet, V., & Darcourt, G. (1999). Serotonin and the frontal lobes. In J. L. Cummings & B. L. Miller (Eds.) The frontal lobes (pp. 125-138). New York: Guilford Press.
32. Robert, P. H., Migneco, O., Koulibaly, M., Bertogliati, C., Dygai, C., Benoît, M., Salame, P., Darcourt, J., & Danion, J. M. (2001). Cingulate and attentional correlates of apathy in Alzheimer's disease. Brain and Cognition, 47, 300-303.
33. Schneider, L. S. (1996). Meta-analysis of controlled pharmacologic trials. International Psychogeriatrics, 8, 375-379.
34. Schneider, L. S. (1999). Pharmacologic management of psychosis in dementia. Journal of Clinical Psychiatry, 60(Suppl. 8), 54-60.
35. Schneider, L. S., Pollock, V. E., & Lyness, S. A. (1990). A meta-analysis of controlled trials of neuroleptic treatment in dementia. Journal of the American Geriatric Society, 38, 553-563.
36. Stern, R. G., Duffelmeyer, M. E., Zemishlani, Z., & Davidson, M. (1991). The use of benzodiazepines in the management of behavioral symptoms in demented patients. Psychiatry Clinical North America, 14, 375-384.
37. Street, J. S., Clark, W. S., Gannon, K. S., Cummings, J. L., Bymaster, F. P., Tamura, R. N., Mitan, S. J., Kadam, D. L., Sanger, T. M., Feldman, P. D., Tollefson, G. D., & Breier, A. (2000). Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: A double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Archives of General Psychiatry, 57, 968-976.
38. Sultzer, D., Gray, K. F., & Gunay, I. (1997). A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia. American Journal Geriatry Psychiatry, 5, 60-69.
39. Sultzer, D. L., Mahler, M. E., Mandelkern, M. A., Cummings, J. L., & Van Gorp, W. G. (1995). The relationship between psychiatric symptoms and regional cortical metabolism in Alzheimer's disease. The Journal of Neuropsychiatry and Clinical Neurosciences, 7, 476-484.
40. Tariot, P. N. (1999). Treatment of agitation in dementia. Journal of Clinical Psychiatry, 60(Suppl. 8), 11-20.
41. Tariot, P. N., Solomon, P. R., Morris, J. C., Kershaw, P., Lilienfeld, S., Ding, C., & the Galantamine USA-10 Study Group. (2000). A 5-month randomized, placebo-controlled trial of galantamine in AD. Neurology, 54, 2269-2276.
42. Teri, L., Hughes, J. P., & Larson, E. B. (1990). Cognitive deterioration in Alzheimer's disease: Behavioral and health factors. Journal of Gerontology, 45, 58-63.
43. Volkow, N. D., Logan, J., Fowler, J. S., Wang, G. J., Gur, R. C., Wong, C., Felder, C., Gatley, S. J., Ding, Y. S., Hitzemann, R., & Pappas, N. (2000). Association between age-related decline in brain dopamine activity and impairment in frontal and cingulate metabolism. American Journal of Psychiatry, 157(1), 75-80.
44. World Health Organization. (1993). The ICD-10-classification of mental and behavioural disorders. Clinical descriptions and diagnostic guidelines. Geneva: Author.